![](https://www.spectral-ai.com/wp-content/uploads/2023/04/Spectral-dark-masthead-1024x370.jpg)
Our Story
Spectral AI is an artificial intelligence company focusing on medical diagnostics, predictive analytics, and ‘Day One’ healing predictions.
-
2013
Spectral AI Incorporated
-
2014
DeepView Generation 1 510(k) clearance
-
2015
First BARDA Contract
-
2016
DeepView Generation 2 (510k) clearance
-
2017
First Defense Health Agency Contract
-
2018
FDA Breakthrough Designation – Burn
-
2019
Burn Proof Concept Clinical Study Initiated
-
2020
DFU Proof of Concept Clinical Study Initiated
-
2021
Secondary BARDA Burn Contract
-
2021
Burn AI Training Study Initiated
-
2021
Admission to Trading on AIM London Exchange
-
2021
First Department of Defense Contract
-
2022
DFU Validation Study Initiated
-
2023
EU DFU Clinical Study Initiation
-
2023
US Burn AI training Study Completed
-
2023
Business Combination Agreement
![](https://www.spectral-ai.com/wp-content/uploads/2023/04/Dark-Background-No-dots-1024x601.jpg)
At The Forefront
of Innovation
Provides faster and more accurate treatment insight, significantly improving patient care and clinical outcomes.
![](https://www.spectral-ai.com/wp-content/uploads/2023/04/Capabilities.png)
![diabetic foot care management background image](https://www.spectral-ai.com/wp-content/uploads/2023/04/Spectral-Dot-Pattern-White-1380x588.png)
Let’s Talk
Want to Learn More About Spectral AI, DeepView®, and our Team?